• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Characterization of the 5-HT(7) receptor. Determination of the pharmacophore for 5-HT(7) receptor agonism and CoMFA-based modeling of the agonist binding site.

作者信息

Vermeulen Erik S, Schmidt Anne W, Sprouse Jeffrey S, Wikström Håkan V, Grol Cor J

机构信息

Department of Medicinal Chemistry, Center for Pharmacy, State University of Groningen, A Deusinglaan 1, NL-9713 AV Groningen, The Netherlands.

出版信息

J Med Chem. 2003 Dec 4;46(25):5365-74. doi: 10.1021/jm030826m.

DOI:10.1021/jm030826m
PMID:14640545
Abstract

On the basis of a set of 20 diverse 5-HT(7) receptor agonists, the pharmacophore for 5-HT(7) receptor agonism was determined. Additionally two CoMFA models were developed, based on different alignments of the agonists. Both models show good correlations between experimental and predictive pK(i) values and show a high degree of similarity. The CoMFA fields were subsequently used to map the agonist binding site of the model of the 5-HT(7) receptor. Important roles in ligand binding are attributed to Asp162 of TM3 (interaction with a protonated nitrogen), and Thr244 of TM5 (interaction with a substituent at an aromatic moiety). Amino acid residues of the aromatic cluster of TM6 are hypothesized to play an important role in ligand binding as pi-pi stacking moieties. Agonists missing a hydrogen-bond-accepting moiety, but possessing an aromatic substituent instead, seem to bind the receptor with high affinity as well by occupying a lipophilic pocket hosted by residues of TM5 and TM6.

摘要

相似文献

1
Characterization of the 5-HT(7) receptor. Determination of the pharmacophore for 5-HT(7) receptor agonism and CoMFA-based modeling of the agonist binding site.
J Med Chem. 2003 Dec 4;46(25):5365-74. doi: 10.1021/jm030826m.
2
Novel 5-HT7 receptor inverse agonists. Synthesis and molecular modeling of arylpiperazine- and 1,2,3,4-tetrahydroisoquinoline-based arylsulfonamides.新型5-HT7受体反向激动剂。基于芳基哌嗪和1,2,3,4-四氢异喹啉的芳基磺酰胺的合成与分子模拟。
J Med Chem. 2004 Oct 21;47(22):5451-66. doi: 10.1021/jm049743b.
3
Optimization of a pharmacophore model for 5-HT4 agonists using CoMFA and receptor based alignment.
Eur J Med Chem. 2006 Jan;41(1):16-26. doi: 10.1016/j.ejmech.2005.07.017. Epub 2005 Nov 15.
4
A comprehensive study on the 5-hydroxytryptamine(3A) receptor binding of agonists serotonin and m-chlorophenylbiguanidine.关于激动剂血清素和间氯苯基双胍对5-羟色胺(3A)受体结合的全面研究。
Bioorg Med Chem. 2009 Aug 15;17(16):5796-805. doi: 10.1016/j.bmc.2009.07.022. Epub 2009 Jul 16.
5
Molecular modeling of the dopamine D2 and serotonin 5-HT1A receptor binding modes of the enantiomers of 5-OMe-BPAT.5-甲氧基-苯丙胺对映体与多巴胺D2和5-羟色胺5-HT1A受体结合模式的分子模拟
Bioorg Med Chem. 1999 Sep;7(9):1805-20. doi: 10.1016/s0968-0896(99)00134-0.
6
Interpretation of scoring functions using 3D molecular fields. Mapping the diacyl-hydrazine-binding pocket of an insect ecdysone receptor.使用3D分子场的评分函数解释。绘制昆虫蜕皮激素受体的二酰肼结合口袋。
J Chem Inf Model. 2007 Jan-Feb;47(1):176-85. doi: 10.1021/ci600317v.
7
Selective pharmacophore models of dopamine D(1) and D(2) full agonists based on extended pharmacophore features.基于扩展药效团特征的多巴胺 D1 和 D2 完全激动剂的选择性药效团模型。
ChemMedChem. 2010 Feb 1;5(2):232-46. doi: 10.1002/cmdc.200900398.
8
Characterization of the molecular fragment that is responsible for agonism of pergolide at serotonin 5-Hydroxytryptamine2B and 5-Hydroxytryptamine2A receptors.对导致培高利特对5-羟色胺2B和5-羟色胺2A受体产生激动作用的分子片段的表征。
J Pharmacol Exp Ther. 2008 Mar;324(3):1136-45. doi: 10.1124/jpet.107.133165. Epub 2007 Dec 20.
9
Identification of putative agouti-related protein(87-132)-melanocortin-4 receptor interactions by homology molecular modeling and validation using chimeric peptide ligands.通过同源分子建模和使用嵌合肽配体进行验证来鉴定假定的刺鼠相关蛋白(87-132)-促黑素皮质素4受体相互作用。
J Med Chem. 2004 Apr 22;47(9):2194-207. doi: 10.1021/jm0303608.
10
Synthesis of new serotonin 5-HT7 receptor ligands. Determinants of 5-HT7/5-HT1A receptor selectivity.新型5-羟色胺5-HT7受体配体的合成。5-HT7/5-HT1A受体选择性的决定因素。
J Med Chem. 2009 Apr 23;52(8):2384-92. doi: 10.1021/jm8014553.

引用本文的文献

1
Design, Synthesis and Biological Evaluation of Novel 1,3,5-Triazines: Effect of Aromatic Ring Decoration on Affinity to 5-HT Receptor.新型 1,3,5-三嗪的设计、合成与生物评价:芳香环修饰对 5-HT 受体亲和力的影响。
Int J Mol Sci. 2022 Nov 1;23(21):13308. doi: 10.3390/ijms232113308.
2
2,5-Di-methyl-bufo-tenine and 2,5-di-methyl-bufo-teni-dine: novel derivatives of natural tryptamines found in toads.2,5-二甲基蟾蜍色胺和2,5-二甲基蟾蜍特尼定:蟾蜍中发现的天然色胺的新型衍生物。
Acta Crystallogr E Crystallogr Commun. 2021 Jan 29;77(Pt 2):190-194. doi: 10.1107/S2056989021000803. eCollection 2021 Feb 1.
3
Low-basicity 5-HT Receptor Agonists Synthesized Using the van Leusen Multicomponent Protocol.
使用范鲁森多组分协议合成低碱性 5-HT 受体激动剂。
Sci Rep. 2017 May 4;7(1):1444. doi: 10.1038/s41598-017-00822-4.
4
Synthesis and structure evaluation of new complex butylarylpiperazin-1-yl derivatives.新型复合丁基芳基哌嗪-1-基衍生物的合成与结构评价
Med Chem Res. 2014;23(3):1519-1536. doi: 10.1007/s00044-013-0740-z. Epub 2013 Sep 3.
5
Serotonin 5-HT7 receptor agents: Structure-activity relationships and potential therapeutic applications in central nervous system disorders.5-羟色胺 5-HT7 受体激动剂:在中枢神经系统疾病中的结构-活性关系和潜在治疗应用。
Pharmacol Ther. 2011 Feb;129(2):120-48. doi: 10.1016/j.pharmthera.2010.08.013. Epub 2010 Oct 20.
6
Phe369(7.38) at human 5-HT(7) receptors confers interspecies selectivity to antagonists and partial agonists.人 5-HT(7) 受体中的 Phe369(7.38) 赋予了拮抗剂和部分激动剂的种属选择性。
Br J Pharmacol. 2010 Mar;159(5):1069-81. doi: 10.1111/j.1476-5381.2009.00481.x. Epub 2009 Nov 18.
7
Techniques: Recent developments in computer-aided engineering of GPCR ligands using the human adenosine A3 receptor as an example.技术:以人类腺苷A3受体为例的GPCR配体计算机辅助工程的最新进展。
Trends Pharmacol Sci. 2005 Jan;26(1):44-51. doi: 10.1016/j.tips.2004.11.006.